Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 17 September 2025 - 24 September 2025

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock and Company Update as of September 24, 2025 Stock Performance & Technical Analysis Cidara’s stock has been on a tear in 2025, delivering triple-digit percentage gains. Year-to-date, CDTX has risen about +173% as of late September Investing, driven by upbeat trial results and investor enthusiasm for its flu program. The stock recently surged over 20% in one day after the Phase…
24 September 2025
··
Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants (none had diabetes, but all had weight-related health issues) and randomly assigned them to various daily doses of the pill…
17 September 2025
·
1 … 8 9 10

Stock Market Today

  • KeyCorp Announces $0.205 Dividend with Cautious Outlook on Sustainability
    January 19, 2026, 8:07 AM EST. KeyCorp (NYSE:KEY) will pay a dividend of $0.205 per share on March 13, representing a 3.9% yield above the industry average. The bank has a decade-long history of dividend payments, growing at 11% annually from $0.30 in 2016 to $0.82 recently. However, its payout ratio is high at 94%, raising concerns about sustainability despite forecasted earnings per share growth of 147% over three years and an expected payout ratio drop to 43%. Earnings have declined 5.7% annually over five years, adding to uncertainty. Analysts urge caution as KeyCorp's dividend payments may be challenging to maintain, though past consistency offers some reassurance.
Go toTop